Russell, N. H., Thomas, A., Hills, R. K., Thomas, I., Gilkes, A., Almuina, N. M., Burns, S., Marsh, L., Vyas, P., Metzner, M., McCarthy, N., Andrew, G., Byrne, J., Sellar, R. S., Kelly, R., Cahalin, P., Overgaard, U. M., Mehta, P., Dennis, M., Knapper, S., Freeman, S. D. (2025). Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00259